cutaneous

Bexarotene (LGD1069) is a retinoid analogue that is used to treat the skin manifestations of cutaneous T cell lymphoma (CTCL).

Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.

Pipobroman (Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.

Bromodiphenhydramine hydrochloride is a new antihistaminic in the control of cutaneous.

BI-135585 is an orally active, selective and potent inhibitor of human 11β-hydroxysteroid dehydrogenase-1 (HSD1) for the study of type 2 diabetes.

Doxylamine Succinate is a pyridine derivate histamine H1 antagonist with pronounced sedative properties. Doxylamine succinate (Decapryn) competitively blocks the histamine H1 receptor and limits the typical allergic and anaphylactic responses, including bronchoconstriction, vasodilation, increased capillary permeability, and spasmodic contraction of the gastrointestinal smooth muscle, caused by actions of histamine on bronchial and gastrointestinal smooth muscles, and on capillaries. This drug also prevents histamine-induced pain and itching of the skin and mucous membranes.

Bivalirudin (BG-8967) is a reversible inhibitor of α- and ζ-thrombin (Kis = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting activities.

Romidepsin (FR 901228) is an HDAC inhibitor that inhibits HDAC1/2/4/6 (IC50=36/47/510/1400 nM). Romidepsin has antitumor activity and can be used for the treatment of peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

HSR6071 is a novel orally active and potent anti-allergic agent with inhibitory effects on passive cutaneous anaphylaxis. HSR6071 showed anti-asthmatic activity in a rat model of experimental asthma.

Peldesine (BCX 34) is an effective, competitive, reversible, and orally active inhibitor of purine nucleoside phosphorylase. Peldesine inhibits T-cell proliferation with an IC50 of 800 nM. Peldesine can be used in research on cutaneous T-cell lymphoma, psoriasis and HIV infection.

Pramiconazole (R126638) is an orally available antifungal compound.Pramiconazole is a candidate for the treatment of dermatophytes and cutaneous yeast infections in seborrheic dermatitis.

DNDI-6148 has anti-experimental cutaneous leishmaniasis activity and can be used to study visceral leishmaniasis by inhibiting Leishmania protozoa cleavage and polyadenylation-specific factor (CPSF3) endonuclease.

Sivifene is a antitumor agent. Sivifene can be used for research on the treatment of cutaneous metastases from cancer.

10-Undecenoic acid zinc salt (Zinc undecylenate), a synthetic or natural fungistatic fatty acid, is used topically in creams against eczemas, fungal infections, ringworm, and other cutaneous conditions. The zinc offers an astringent action.

Hexyl nicotinate (AI3 15769) is a cutaneous vasodilator and can be used in research on non-immunologic contact urticaria on the scalp, face, and back.

Remetinostat (SHP-141), a hydroxamic acid-based inhibitor of histone deacetylase enzymes, is currently being developed for the treatment of cutaneous T-cell lymphoma.

Miltefosine (HePC) is the treatment of visceral and cutaneous leishmaniasis drug , and is proceeding clinical trials for this in several countries. Several medical agents produce some potency against visceral or cutaneous leishmaniasis, however a 2005 survey concluded that miltefosine is the only effective oral treatment for both forms of leishmaniasis.

Amantanium bromide (Amantanil bromidum) is a quaternary ammonium antibacterial/antifugal agent useful as a surgical antiseptic and for the topical therapy of mucous and cutaneous infections.

Bexarotene D4 is a deuterium-labeled Bexarotene (LGD1069). Bexarotene is a selective RXR agonist used in the treatment of cutaneous T-cell lymphoma.

TMP780 is an inverse RORγt agonist (IC50: 13 nM). RORγt is a tractable drug target for the treatment of cutaneous inflammatory disorders.

Forodesine (BCX-1777) is an orally active and potent purine nucleoside phosphorylase (PNP) inhibitor, a new purine nucleoside analog, inhibitor of human lymphocyte proliferation, induces apoptosis in leukemic cells by increasing dGTP levels, and may be useful in the study of cutaneous T-cell lymphomas.

(±)-CPSI-1306 (2-(3-(2,4-Difluorophenyl)-4,5-dihydroisoxazol-5-yl)-1-morpholinoethan-1-one) is a macrophage migration inhibitory factor (MIF) antagonist and can be used in studies about non-insulin-dependent diabetes mellitus (NIDDM) and the prevention of the deleterious cutaneous effects of acute and chronic UVB exposure.

ISOCROMIL, a chromone compound, exhibits anti-allergic properties. It plays a significant role as a mediator release inhibitor in the treatment of passive cutaneous anaphylaxis reactions and is also important as an anti-asthmatic agent.

Sudexanox, a flavonoid derivative, is utilized in the treatment of allergies, atopic asthma, and asthmatic bronchitis. In preclinical studies, Sudexanox has demonstrated potent activity in an IgE-induced passive cutaneous anaphylaxis model in rats.